Cxbladder Detect test – pro
Cxbladder is a genomic urine test that purpots to t quickly and accurately detect or rule out bladder cancer. The test combines clinical risk factor markers with genetic information, measuring five biomarker genes to detect the presence or absence of bladder cancer. There is a tried fo these tests, and Cxbladder Detect can be used as an adjunct to cystoscopy or as a substitute for other urine-based tests or imaging procedures. According to the manufacturer, levels of messenger RNA (mRNA) of five biomarker genes, including MDK, HOXA13, CDC2, IGFBP5, CXCR2, are believed to be in higher concentrations in urine samples of patients with bladder cancer.
The National Comprehensive Cancer Network (2019) Clinical Practice Guidelines state the following regarding the use of available urinary biomarkers:3 o “Many of these [urinary molecular tests] have a better sensitivity for detecting bladder cancer than urinary cytology, but specificity is lower. Considering this, evaluation of urinary urothelial tumor markers may be considered during surveillance of high-risk non-muscle invasive bladder cancer. However, it remains unclear whether these tests offer additional information that is useful for detection and management of non-muscle-invasive bladder tumors. Therefore, the panel consider this to be a category 2B
Davidson, PJ, McGeoch, G, Shand, B. Inclusion of a molecular marker of bladder cancer in a clinical pathway for investigation of haematuria may reduce the need for cystoscopy. NZ Med J 2019; 132:1497.
NCCN Baldder Cancer 2021
Koya M, Osborne S, Chemasle C, Porten S, Schuckman A, Kennedy-Smith A. An evaluation of the real world use and clinical utility of the Cxbladder Monitor assay in the follow-up of patients previously treated for bladder cancer. BMC Urology. 2020; 20:12.
Davidson P, McGeoch G, Shand B. Assessment of a clinical pathway for investigation of haematuria that reduces the need for cystoscopy. NZ Med J 2020. 133:1527
Chu C, Li K, Meng M, Porten S. PD63-12: Use of Cxbladder Monitor during the COVID-19 Pandemic to reduce the frequency of surveillance cystoscopy. J Urol 2021; 206(3):1142erecommendation.”